Charles River Laboratories (CRL)

Currency in USD
149.78
-0.55(-0.37%)
Closed·
After Hours
148.02-1.76(-1.18%)
·
CRL Scorecard
Full Analysis
Management has been aggressively buying back shares
CRL is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
149.52154.98
52 wk Range
91.86230.02
Key Statistics
Prev. Close
149.78
Open
153.37
Day's Range
149.52-154.98
52 wk Range
91.86-230.02
Volume
1.36M
Average Volume (3m)
947.02K
1-Year Change
-25.1%
Book Value / Share
68.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
165.31
Upside
+10.37%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Charles River Laboratories Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories Earnings Call Summary for Q1/2025

  • Charles River Labs beats Q1 2025 expectations with EPS of $2.34 and revenue of $984.2M, stock surges 14.92% pre-market
  • Company raises full-year guidance, projecting EPS of $9.30-$9.80 despite anticipated organic revenue decline of 2.5-4.5%
  • Alternative Methods Advancement Project launched, contributing $200M in annual revenue; focus on expanding non-animal platforms
  • Operating margin improves to 19.1%; free cash flow increases to $112.4M from $50.7M last year
  • Potential $50M revenue impact from reduced chronic NHP studies due to FDA's animal testing reduction initiative
Last Updated: 07/05/2025, 16:16
Read Full Transcript

Compare CRL to Peers and Sector

Metrics to compare
CRL
Peers
Sector
Relationship
P/E Ratio
−106.5x21.7x−0.5x
PEG Ratio
0.910.050.00
Price/Book
2.2x2.8x2.6x
Price / LTM Sales
1.8x3.1x3.3x
Upside (Analyst Target)
13.5%15.2%43.4%
Fair Value Upside
Unlock7.9%7.1%Unlock

Analyst Ratings

5 Buy
12 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 165.31
(+10.37% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
3.12 / 2.50
Revenue / Forecast
1.03B / 984.86M
EPS Revisions
Last 90 days

CRL Income Statement

People Also Watch

58.34
AAP
-3.46%
87.55
QRVO
+3.99%
178.95
IQV
+0.82%
67.50
SKY
-2.39%
120.17
MIDD
+1.58%

FAQ

What Stock Exchange Does Charles River Laboratories Trade On?

Charles River Laboratories is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Charles River Laboratories?

The stock symbol for Charles River Laboratories is "CRL."

What Is the Charles River Laboratories Market Cap?

As of today, Charles River Laboratories market cap is 7.37B.

What Is Charles River Laboratories's Earnings Per Share (TTM)?

The Charles River Laboratories EPS (TTM) is -1.37.

When Is the Next Charles River Laboratories Earnings Date?

Charles River Laboratories will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is CRL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Charles River Laboratories Stock Split?

Charles River Laboratories has split 0 times.

How Many Employees Does Charles River Laboratories Have?

Charles River Laboratories has 19400 employees.

What is the current trading status of Charles River Laboratories (CRL)?

As of 08 Aug 2025, Charles River Laboratories (CRL) is trading at a price of 149.78, with a previous close of 149.78. The stock has fluctuated within a day range of 149.52 to 154.98, while its 52-week range spans from 91.86 to 230.02.

What Is Charles River Laboratories (CRL) Price Target According to Analysts?

The average 12-month price target for Charles River Laboratories is USD165.3125, with a high estimate of USD200 and a low estimate of USD108. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +10.37% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.